HuGE Literature Finder
Records 1-13
|
Biological Significance of TERT Promoter Mutation in Papillary Urothelial Neoplasm of Low Malignant Potential.
Histopathology 2017 Nov . Wang Chung-Chieh, Huang Chao-Yuan, Jhuang Yu-Lin, Chen Chih-Chi, Jeng Yung-Mi |
|
Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder.
Virchows Archiv : an international journal of pathology 2017 Jun . Rodriguez Pena Maria Del Carmen, Tregnago Aline C, Eich Marie-Lisa, Springer Simeon, Wang Yuxuan, Taheri Diana, Ertoy Dilek, Fujita Kazutoshi, Bezerra Stephania M, Cunha Isabela W, Raspollini Maria Rosaria, Yu Lijia, Bivalacqua Trinity J, Papadopoulos Nickolas, Kinzler Kenneth W, Vogelstein Bert, Netto George |
|
HRAS T81C polymorphism modulates risk of urinary bladder cancer and predicts advanced tumors in ethnic Kashmiri population.
Urologic oncology 2013 May 31 (4): 487-92. Pandith Arshad A, Shah Zafar A, Khan Nighat P, Baba Khalil M, Wani M Saleem, Siddiqi Mushtaq |
|
Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Human pathology 2012 Oct 43 (10): 1573-82. Juanpere Nuria, Agell Laia, Lorenzo Marta, de Muga Silvia, López-Vilaró Laura, Murillo Raquel, Mojal Sergi, Serrano Sergio, Lorente José A, Lloreta Josep, Hernández Silv |
|
H-ras mutation detection in bladder cancer by COLD-PCR analysis and direct sequencing.
Urologia internationalis 2012 88 (3): 350-7. Wang Ai-Xiang, Chang Ji-Wu, Li Chang-Ying, Liu Kun, Lin Ying- |
|
Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events.
International journal of cancer. Journal international du cancer 2011 Jul 129 (1): 78-87. Serizawa Reza R, Ralfkiaer Ulrik, Steven Kenneth, Lam Gitte W, Schmiedel Sven, Schüz Joachim, Hansen Alastair B, Horn Thomas, Guldberg P |
|
A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.
PloS one 2011 6 (4): e18583. Sjödahl Gottfrid, Lauss Martin, Gudjonsson Sigurdur, Liedberg Fredrik, Halldén Christer, Chebil Gunilla, Månsson Wiking, Höglund Mattias, Lindgren Dav |
|
FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.
PloS one 2010 5 (11): e13821. Kompier Lucie C, Lurkin Irene, van der Aa Madelon N M, van Rhijn Bas W G, van der Kwast Theo H, Zwarthoff Ellen |
|
Activation of RAS Family Genes in Urothelial Carcinoma.
The Journal of urology 2009 Mar . Boulalas I, Zaravinos A, Karyotis I, Delakas D, Spandidos DA |
|
Polymorphisms in DNA repair and metabolic genes in bladder cancer.
Carcinogenesis 2004 May 25 (5): 729-34. Sanyal Somali, Festa Fabiola, Sakano Shigeru, Zhang Zhengzhong, Steineck Gunnar, Norming Ulf, Wijkström Hans, Larsson Per, Kumar Rajiv, Hemminki Ka |
|
A single nucleotide polymorphism in the human H-ras proto-oncogene determines the risk of urinary bladder cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2003 Jan 12 (1): 68-70. Johne Andreas, Roots Ivar, Brockmöller Jürg |
|
HRAS1 variable number of tandem repeats polymorphism and risk of bladder cancer.
International journal of cancer. Journal international du cancer 2002 Aug 100 (4): 414-8. van Gils Carla H, Conway Kathleen, Li Yu, Taylor Jack |
|
Activated H-ras gene mutations in transitional cell carcinoma of urinary bladder in a Kashmiri population.
Tumori 0 96 (6): 993-8. Pandith Arshad Ahmad, Shah Zafar, Rasool Roohi, Dil-Afroze , Yousuf Adfar, Parveen Nighat, Wani Saleem, Siddiqi Musht |
- Page last reviewed:Mar 16, 2019
- Page last updated:Apr 02, 2020
- Content source: